Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab

Autor: Didier Hannequin, Jared R. Brosch, B. Joy Snider, Anna Santacruz, Anne M. Fagan, Suman Jayadev, William S. Brooks, Colin L. Masters, Erik D. Roberson, Mario Masellis, Susan Mills, Christopher H. Dyck, Florence Pasquier, Paulo Fontoura, Bruno Dubois, Monika Baudler, Lawrence S. Honig, Doug R. Galasko, James J. Lah, Peter J. Snyder, David Wallon, Geoffrey A. Kerchner, Eric McDade, Guoqiao Wang, Andrew J. Aschenbrenner, Jason Hassenstab, Roy Yaari, Ghulam M. Surti, Raquel Sánchez-Valle, Jérémie Pariente, Stephen Salloway, Carlos Cruchaga, Randall J. Bateman, Ivonne Z. Jimenez-Velazquez, Robert A. Koeppe, John C. Morris, Serge Gauthier, Clifford R. Jack, Sarah B. Berman, Alison Goate, Catherine J. Mummery, Martin R. Farlow, Karen C. Holdridge, Rachelle S. Doody, Tammie L.S. Benzinger, Scott W. Andersen, Chengjie Xiong, Ging-Yuek Robin Hsiung, Roger Clarnette, Paul Delmar, Maïté Formaglio, Mark A. Mintun, Kelley Coalier, John R. Sims, Brian A. Gordon, David B. Clifford

Publikováno v: Alzheimer's & Dementia. 16

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2282514a79bf4577741d6ff675173fc7
https://doi.org/10.1002/alz.041129